Abstract
Scleroderma-like or pseudo-scleroderma disorders are a wide group of diseases with various etiologies that lead to skin fibrosis therefore mimicking systemic sclerosis. Although they all have skin thickening in common, the distribution, pattern, and character of the involvement as well as systemic manifestations vary between them. The importance of recognizing these mimics resides in their different prognoses and treatment options. A complete clinical history, detailed physical exam as well as laboratory studies and skin biopsy can help differentiate them.
Since the list of scleroderma mimics is long, this chapter will focus on a few key disorders (eosinophilic fasciitis, scleredema, scleromyxedema, nephrogenic systemic fibrosis, diabetic cheiroarthropathy, and lipodermatosclerosis). Other rare conditions, such as metabolic diseases (phenylketonuria, porphyria cutanea tarda), exposure to chemical agents such as bleomycin, vinyl chloride, tryptophan and toxic oil syndrome, and genetic diseases such as progeria, Werner’s syndrome, and Stiff Man Syndrome, which can also cause skin sclerosis will not be discussed.
The absence of typical SSc features such as Raynaud’s phenomenon, antinuclear antibodies, and nailfold capillary changes should raise the index of suspicion for an alternative diagnosis.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Nashel J, Steen V. Scleroderma mimics. Curr Rheumatol Rep. 2012;14(1):39–46.
Boin F, Hummers LK. Scleroderma-like fibrosing disorders. Rheum Dis Clin North Am. 2008;34(1):199–220.
Fujimoto M, Sato S, Ihn H, Kikuchi K, Yamada N, Takehara K. Serum aldolase level is a useful indicator of disease activity in eosinophilic fasciitis. J Rheumatol. 1995;22(3):563–5.
Nashel J, Steen V. Elevation of aldolase in eosinophilic fasciitis. Arthritis Rheum. 2013;62(Suppl):S2011 (abstract).
Barnes L, Rodnan GP, Medsger TA, Short D. Eosinophilic fasciitis. A pathologic study of twenty cases. Am J Pathol. 1979;96(2):493–518.
Baumann F, Bruhlmann P, Andreisek G, Michel BA, Marincek B, Weishaupt D. MRI for diagnosis and monitoring of patients with eosinophilic fasciitis. AJR Am J Roentgenol. 2005;184(1):169–74.
Bischoff L, Derk CT. Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol. 2008;47(1):29–35.
Lebeaux D, Francès C, Barete S, Wechsler B, Dubourg O, Renoux J, Maisonobe T, Benveniste O, Gatfossé M, Bourgeois P, Amoura Z, Cacoub P, Piette JC, Sène D. Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients. Rheumatology (Oxford). 2012;51(3):557–61.
Beers WH, Ince A, Moore TL. Scleredema adultorum of Buschke: a case report and review of the literature. Semin Arthritis Rheum. 2006;35(6):355–9.
Rho YW, Suhr KB, Lee JH, Park JK. A clinical observation of scleredema adultorum and its relationship to diabetes. J Dermatol. 1998;25(2):103–7.
Allam M, Ghozzi M. Scleromyxedema: a case report and review of the literature. Case Rep Dermatol. 2013;5(2):168–75. doi:10.1159/000353178.
Gonzalez J, Palangio M, Schwartz J, Klainer AS, Bisaccia E. Scleromyxedema with dermato-neuro syndrome. J Am Acad Dermatol. 2000;42(5 Pt 2):927–8.
Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore). 2008;87(1):10–20.
Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol. 2008;66(2):191–9.
Weller A, Barber JL, Olsen OE. Gadolinium and nephrogenic systemic fibrosis: an update. Pediatr Nephrol. 2013. [Epub ahead of print].
Elmholdt TR, Buus NH, Ramsing M, Olesen AB. Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial. J Eur Acad Dermatol Venereol. 2013;27(6):779–84.
Abate M, Schiavone C, Salini V, Andia I. Management of limited joint mobility in diabetic patients. Diabetes Metab Syndr Obes. 2013;6:197–207.
Miteva M, Romanelli P, Kirsner RS. Lipodermatosclerosis. Dermatol Ther. 2010;23(4):375–88.
Choonhakarn C, Chaowattanapanit S. Lipodermatosclerosis: improvement noted with hydroxychloroquine and pentoxifylline. J Am Acad Dermatol. 2012;66(6):1013–4.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Salazar, G.A., Steen, V.D., Mayes, M.D. (2014). Systemic Sclerosis Mimics. In: Mayes, M. (eds) A Visual Guide to Scleroderma and Approach to Treatment. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0980-3_9
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0980-3_9
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-0979-7
Online ISBN: 978-1-4939-0980-3
eBook Packages: MedicineMedicine (R0)